France Generics Market Summary, Competitive Analysis and Forecast, 2017-2026
France Generics Market Summary, Competitive Analysis and Forecast, 2017-2026
Abstract
Summary
Generics in France industry profile provides top-line qualitative and quantitative summary information including: market size (value 2017-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The French generics market had total revenues of $4.8 billion in 2021, representing a compound annual growth rate (CAGR) of 3.8% between 2016 and 2021.
- Market consumption volume increased with a CAGR of 1.3% between 2016 and 2021, to reach a total of 85.0 % in 2021.
- Over the past five years, the French generics market recorded growth of 3.3%. Growth in the market has been driven by demographic trends.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in France
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in France
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the France generics market with five year forecasts
Reasons to Buy
- What was the size of the France generics market by value in 2021?
- What will be the size of the France generics market in 2026?
- What factors are affecting the strength of competition in the France generics market?
- How has the market performed over the last five years?
- How large is France’s generics market in relation to its regional counterparts?
Content
Table of Contents
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What are the strengths/weaknesses of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How did the COVID-19 pandemic impact leading players?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Limited
8.2. Pfizer Inc.
8.3. Les Laboratoires Servier
8.4. Sanofi SA
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
List of Tables
Table 1: France generics market value: $ million, 2016-21
Table 2: France generics market volume: %, 2016-21
Table 3: France generics market geography segmentation: $ million, 2021
Table 4: France generics market value forecast: $ million, 2021-26
Table 5: France generics market volume forecast: %, 2021-26
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Pfizer Inc.: key facts
Table 10: Pfizer Inc.: Annual Financial Ratios
Table 11: Pfizer Inc.: Key Employees
Table 12: Pfizer Inc.: Key Employees Continued
Table 13: Les Laboratoires Servier: key facts
Table 14: Les Laboratoires Servier: Key Employees
Table 15: Sanofi SA: key facts
Table 16: Sanofi SA: Annual Financial Ratios
Table 17: Sanofi SA: Key Employees
Table 18: Sanofi SA: Key Employees Continued
Table 19: France size of population (million), 2017-21
Table 20: France gdp (constant 2005 prices, $ billion), 2017-21
Table 21: France gdp (current prices, $ billion), 2017-21
Table 22: France inflation, 2017-21
Table 23: France consumer price index (absolute), 2017-21
Table 24: France exchange rate, 2017-21
List of Figures
Figure 1: France generics market value: $ million, 2016-21
Figure 2: France generics market volume: %, 2016-21
Figure 3: France generics market geography segmentation: % share, by value, 2021
Figure 4: France generics market value forecast: $ million, 2021-26
Figure 5: France generics market volume forecast: %, 2021-26
Figure 6: Forces driving competition in the generics market in France, 2021
Figure 7: Drivers of buyer power in the generics market in France, 2021
Figure 8: Drivers of supplier power in the generics market in France, 2021
Figure 9: Factors influencing the likelihood of new entrants in the generics market in France, 2021
Figure 10: Factors influencing the threat of substitutes in the generics market in France, 2021
Figure 11: Drivers of degree of rivalry in the generics market in France, 2021
Summary
Generics in France industry profile provides top-line qualitative and quantitative summary information including: market size (value 2017-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The French generics market had total revenues of $4.8 billion in 2021, representing a compound annual growth rate (CAGR) of 3.8% between 2016 and 2021.
- Market consumption volume increased with a CAGR of 1.3% between 2016 and 2021, to reach a total of 85.0 % in 2021.
- Over the past five years, the French generics market recorded growth of 3.3%. Growth in the market has been driven by demographic trends.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in France
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in France
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the France generics market with five year forecasts
Reasons to Buy
- What was the size of the France generics market by value in 2021?
- What will be the size of the France generics market in 2026?
- What factors are affecting the strength of competition in the France generics market?
- How has the market performed over the last five years?
- How large is France’s generics market in relation to its regional counterparts?
Table of Contents
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What are the strengths/weaknesses of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How did the COVID-19 pandemic impact leading players?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Limited
8.2. Pfizer Inc.
8.3. Les Laboratoires Servier
8.4. Sanofi SA
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
List of Tables
Table 1: France generics market value: $ million, 2016-21
Table 2: France generics market volume: %, 2016-21
Table 3: France generics market geography segmentation: $ million, 2021
Table 4: France generics market value forecast: $ million, 2021-26
Table 5: France generics market volume forecast: %, 2021-26
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Pfizer Inc.: key facts
Table 10: Pfizer Inc.: Annual Financial Ratios
Table 11: Pfizer Inc.: Key Employees
Table 12: Pfizer Inc.: Key Employees Continued
Table 13: Les Laboratoires Servier: key facts
Table 14: Les Laboratoires Servier: Key Employees
Table 15: Sanofi SA: key facts
Table 16: Sanofi SA: Annual Financial Ratios
Table 17: Sanofi SA: Key Employees
Table 18: Sanofi SA: Key Employees Continued
Table 19: France size of population (million), 2017-21
Table 20: France gdp (constant 2005 prices, $ billion), 2017-21
Table 21: France gdp (current prices, $ billion), 2017-21
Table 22: France inflation, 2017-21
Table 23: France consumer price index (absolute), 2017-21
Table 24: France exchange rate, 2017-21
List of Figures
Figure 1: France generics market value: $ million, 2016-21
Figure 2: France generics market volume: %, 2016-21
Figure 3: France generics market geography segmentation: % share, by value, 2021
Figure 4: France generics market value forecast: $ million, 2021-26
Figure 5: France generics market volume forecast: %, 2021-26
Figure 6: Forces driving competition in the generics market in France, 2021
Figure 7: Drivers of buyer power in the generics market in France, 2021
Figure 8: Drivers of supplier power in the generics market in France, 2021
Figure 9: Factors influencing the likelihood of new entrants in the generics market in France, 2021
Figure 10: Factors influencing the threat of substitutes in the generics market in France, 2021
Figure 11: Drivers of degree of rivalry in the generics market in France, 2021
Related Report
